Lower risk for bleeding without increase in ischemic events seen for patients with acute coronary syndrome.
Developed by the Serum Institute of India, the rBCG product, which has been modified to improve its immunogenicity and safety, was evaluated in phase 1/2 clinical trials in Europe in patients with ...